» Articles » PMID: 9482395

New Hepatitis B Virus Mutant Form in a Blood Donor That is Undetectable in Several Hepatitis B Surface Antigen Screening Assays

Overview
Journal Transfusion
Specialty Hematology
Date 1998 Mar 3
PMID 9482395
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Envelope mutant forms of hepatitis B virus (HBV), impairing HBV antibody recognition, have been reported with mutations in single or multiple sites of the hepatitis B surface antigen (HBsAg) group-specific "a" determinant. Blood donors infected with such an HBsAg mutant form of HBV may escape detection by HBsAg screening assays and therefore may affect the safety of the blood supply.

Case Report: A repeat blood donor became HBsAg-reactive in an enzyme immunoassay. Confirmatory testing yielded negative results for HBsAg in a radioimmunoassay and in four enzyme immunoassays used in blood donor screening. The specificity of the HBsAg reactivity in the first enzyme immunoassay was confirmed by HBsAg neutralization with antibody to HBsAg. Additional HBV confirmatory test results were positive for antibody to hepatitis B core antigen and antibody to hepatitis B e antigen; negative for antibody to HBsAg and for hepatitis B e antigen; and positive for HBV DNA. DNA sequence analysis of the "a" determinant region of HBsAg revealed amino acid substitutions from Q (Gln) to R (Arg) at codon 129 and from M (Met) to T (Thr) at codon 133.

Conclusion: This case illustrates the presence of HBsAg mutant forms of HBV in a West European blood donor population that were undetected by several HBsAg screening assays. Adaptation of HBsAg screening is indicated to overcome deficiencies in sensitivity in detecting HBsAg mutant forms of HBV. Screening for antibody to hepatitis B core antigen or HBV DNA may also detect blood donors infected with HBsAg mutant forms of HBV

Citing Articles

Low Prevalence of Anti-HBc Antibody and Lack of HBV DNA Among HBsAg-Negative Blood Donors in Iran: A Cross-sectional Study and Review of Literature.

Hedayati-Moghaddam M, Tehranian F, Mosavat A, Miri R, Ahmadi Ghezeldasht S Arch Iran Med. 2024; 27(6):305-312.

PMID: 38855800 PMC: 11264625. DOI: 10.34172/aim.28579.


Seroprevalence of Viral Hepatitis B and C among Blood Donors in the Northern Region of Riyadh Province, Saudi Arabia.

Alqahtani S, Alsagaby S, Ahmad Mir S, Alaidarous M, Bin Dukhyil A, Alshehri B Healthcare (Basel). 2021; 9(8).

PMID: 34442071 PMC: 8394786. DOI: 10.3390/healthcare9080934.


Laboratory Diagnosis and Monitoring of Viral Hepatitis.

Prasidthrathsint K, Stapleton J Gastroenterol Clin North Am. 2019; 48(2):259-279.

PMID: 31046974 PMC: 10461253. DOI: 10.1016/j.gtc.2019.02.007.


Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Cicchetti A, Berrino A, Casini M, Codella P, Facco G, Fiore A Blood Transfus. 2016; 14(4):287-386.

PMID: 27403740 PMC: 4942318. DOI: 10.2450/2016.0065-16.


HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.

Archampong T, Boyce C, Lartey M, Sagoe K, Obo-Akwa A, Kenu E Antivir Ther. 2016; 22(1):13-20.

PMID: 27167598 PMC: 5106338. DOI: 10.3851/IMP3055.